Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer

Study:

Evaluation of the Effect of 25-OH-Vitamin D3 Therapy on 15-Prostaglandin Dehydrogenase Expression in Primary Tumor and Normal Colorectal Mucosa in Patients With Colorectal Cancer

Rationale:

n/a

Purpose:

This pilot clinical trial studies cholecalciferol in treating patients with colorectal cancer. The use of cholecalciferol may slow disease progression in patients with colorectal cancer.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum
Signet Ring Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage I Colon Cancer
Stage I Rectal Cancer
Dietary Supplement: cholecalciferol
Procedure: biopsy
Genetic: protein expression analysis
Other: enzyme-linked immunosorbent assay
Other: laboratory biomarker analysis
Genetic: reverse transcriptase-polymerase chain reaction
Phase 0

Verified by Case Comprehensive Cancer Center December, 2013

Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT01403103

Study Type: Interventional

Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44118
United States

Smitha Krishnamurthi, MD., Principal Investigator
Matthew Kalady, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site